Board of Directors

Harry J. F. Bloomfield, QC., M.B.A.

Chaiman & Director
Harry J. F. Bloomfield, QC., M.B.A., is a lawyer, business manager and philanthropist. Born in Montreal, Quebec, he received a Bachelor of Arts degree from McGill University in 1965, a Bachelor of Civil Law degree from Université de Montréal in 1968, and joined the Bar of Quebec in 1969. Bloomfield received a Master of Business Administration from the Harvard Graduate School of Business Administration in 1971. He was appointed Queen's Counsel in 1991. Bloomfield has served on numerous boards, public and private, including Heller Financial Canada (now part of GE Capital); Banco Comercial Português, the Canadian subsidiary of Sottomayor Bank of Portugal; British Controlled Oilfields, Genoil Inc., Balkan Resources Inc., and Wi2Wi Inc. In May 2011, he was elected to the Board of Directors of Miraculins Inc. (TSX-V:MOM), a medical diagnostic company, and in April 2012 he was elected the board’s Chairman.

Christopher J. Moreau

CEO and Director
Mr. Moreau is the CEO of Algernon Pharmaceuticals Inc. and a member of the company's board of directors. With over 30 years of executive management experience overall, including 15 years in CEO roles, he has proven achievements in operations management, acquisitions, licensing, and integration. Mr. Moreau also has significant experience managing biotechnology research programs, and a deep expertise in business development and capital markets, having raised more than $50 million. He has also been featured on numerous business television and social media interviews, and is a highly skilled communicator and sought-after speaker, recently appearing as a guest Lecturer for the University of East London, Pharmacology program.

Raj Attariwala, MD, PhD.

Director
Dr. Attariwala is a dual board certified Radiologist and Nuclear Medicine physician certified in both Canada and the United States. He received his formal medical training at University of British Columbia with periods of specialized medical training at Memorial Sloan Kettering Cancer Centre (New York), UCLA and USC. He holds a doctorate in Biomedical Engineering from Northwestern University (Evanston, IL).

Dr. Mark Williams, PhD.

Director
Dr. Williams was a co–founder of the Algernon Pharmaceuticals drug repurposing program and was actively engaged as the Company’s Chief Scientific Officer until March 1st, 2021. He has over 15 years of experience in drug and medical device development and has authored multiple patents. He has specific expertise and skill sets in taking companies from the discovery process to Phase 2 trials including cGMP manufacturing and toxicology. He holds a PhD in Microbiology from the University of Alberta, and an MBA from the University of Manitoba.

Ambassador (Rtd) Howard Gutman

Director
Ambassador (Rtd) Gutman acted, during his distinguished career over the past three decades, as a leading American and international lawyer, and served in a number of high-profile appointments for the government of the United States, including Ambassador to Belgium, and Special Assistant to the Director of the FBI for Counter-Intelligence and Counter-Terrorism. During his legal career he served as a United States Supreme Court and federal appellate court law clerk prior to entering private practice in Washington, DC., where in addition to legal practice, he served as advisor to candidates for President, Governor and the U.S. Senate.
Share via
Copy link
Powered by Social Snap